Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CFO Sells 23,030 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CFO James William Rogers sold 23,030 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.97, for a total value of $1,058,689.10. Following the transaction, the chief financial officer now directly owns 164,750 shares in the company, valued at $7,573,557.50. The trade was a 12.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

James William Rogers also recently made the following trade(s):

• On Tuesday, February 18th, James William Rogers sold 31,780 shares of Tempus AI stock. The shares were sold at an average price of $82.33, for a total value of $2,616,447.40.
• On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The shares were sold at an average price of $67.57, for a total value of $588,669.84.

Tempus AI Price Performance

TEM stock traded up $3.31 during trading on Friday, hitting $51.35. 9,890,627 shares of the company traded hands, compared to its average volume of 5,060,523. The stock's 50-day simple moving average is $56.35 and its 200 day simple moving average is $51.38. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Kovitz Investment Group Partners LLC purchased a new position in Tempus AI during the third quarter valued at approximately $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tempus AI in the fourth quarter valued at approximately $1,091,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Tempus AI in the fourth quarter valued at approximately $178,000. Captrust Financial Advisors acquired a new stake in Tempus AI in the third quarter valued at approximately $2,726,000. Finally, abrdn plc acquired a new stake in Tempus AI in the fourth quarter valued at approximately $2,784,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of recent research reports. Morgan Stanley raised their price objective on Tempus AI from $50.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. downgraded Tempus AI from an "overweight" rating to a "neutral" rating and raised their price objective for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Wolfe Research cut Tempus AI from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, TD Cowen reiterated a "buy" rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Tempus AI presently has a consensus rating of "Moderate Buy" and an average price target of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.